Search results for "NAK"

showing 10 items of 469 documents

The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes

2018

Background Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. Objective We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. Method After literature search, the available evidence has bee…

0301 basic medicineInterleukin-1betaInflammationAnakinra; Cardiovascular risk; Diabetes; IL-1β; Pathogenesis; Rheumatoid arthritis; Therapy; PharmacologyType 2 diabetesPathogenesisDiabeteProinflammatory cytokinePathogenesisArthritis Rheumatoid03 medical and health sciencesImmune systemPathogenesiDiabetes mellitusmedicineHumansRheumatoid arthritisRheumatoid arthritiPharmacologyAnakinrabusiness.industryDiabetesAntirheumatic AgentReceptors Interleukin-1General Medicinemedicine.diseaseCardiovascular riskSettore MED/16 - Reumatologia030104 developmental biologyAnakinraDiabetes Mellitus Type 2IL-1βRheumatoid arthritisAntirheumatic AgentsImmunologyTherapymedicine.symptombusinessmedicine.drugHuman
researchProduct

Interleukin 1α: a comprehensive review on the role of IL-1α in the pathogenesis and treatment of autoimmune and inflammatory diseases.

2021

Abstract The interleukin (IL)-1 family member IL-1α is a ubiquitous and pivotal pro-inflammatory cytokine. The IL-1α precursor is constitutively present in nearly all cell types in health, but is released upon necrotic cell death as a bioactive mediator. IL-1α is also expressed by infiltrating myeloid cells within injured tissues. The cytokine binds the IL-1 receptor 1 (IL-1R1), as does IL-1β, and induces the same pro-inflammatory effects. Being a bioactive precursor released upon tissue damage and necrotic cell death, IL-1α is central to the pathogenesis of numerous conditions characterized by organ or tissue inflammation. These include conditions affecting the lung and respiratory tract, …

0301 basic medicineMyocarditisil-1βmedicine.medical_treatmentAutoimmunity Cancer Cytokines IL-1 IL-1αIL-1β Inflammation Interleukin 1 Receptor Antagonist Protein Receptors Interleukin-1 SARS-CoV-2 COVID-19 Interleukin-1alpha Humansil-1αImmunologyreceptorsInflammationmedicine.disease_causeAutoimmunityPathogenesis03 medical and health sciences0302 clinical medicineSettore MED/38 - Pediatria Generale E Specialisticail-1Interleukin-1alphamedicinecancerImmunology and AllergyHumans030203 arthritis & rheumatologyAnakinrabusiness.industrySARS-CoV-2autoimmunityInterleukinCOVID-19Receptors Interleukin-1medicine.diseasecytokinesRilonaceptInterleukin 1 Receptor Antagonist Protein030104 developmental biologyCytokineinflammationImmunologyautoimmunity; cancer; cytokines; il-1; il-1α; il-1β; inflammation; humans; interleukin 1 receptor antagonist protein; receptors interleukin-1; SARS-COV-2; COVID-19; interleukin-1alphamedicine.symptombusinessinterleukin-1medicine.drugAutoimmunity reviews
researchProduct

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phas…

2018

IF 5.503 (2017); International audience; In preclinical models, IL-1β inhibition could enhance the efficacy of fluorouracil (5-FU). In this phase 2 study, we assessed the activity and safety of 5-FU plus bevacizumab and anakinra (an IL-1β and α inhibitor) in patients with metastatic colorectal (mCRC) refractory to chemotherapy and anti-angiogenic therapy. Eligible patients had unresectable mCRC; were refractory or intolerant to fluoropyrimidine, irinotecan, oxaliplatin, anti-VEGF therapy, and anti-EGFR therapy (for tumors with wild-type KRAS). Patients were treated with a simplified acid folinic plus 5-FU regimen and bevacizumab (5 mg/kg) both administered by intravenous infusion for 30 min…

0301 basic medicinelcsh:Immunologic diseases. Allergymedicine.medical_specialtyBevacizumabImmunologyPhases of clinical research[SDV.CAN]Life Sciences [q-bio]/CancerNeutropeniaGastroenterologyclicial trial optimizationlcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicinetherapeutic trialsImmunology and Allergyil1colorectalnew targetsAnakinrabusiness.industryclinical trialmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOxaliplatinIrinotecanRegimen030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesischemoimmunotherapymdscbusinesslcsh:RC581-607medicine.drugOncoimmunology
researchProduct

Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response:…

2021

Objective: To describe the role of biotechnological therapies in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS) and to identify any predictor of complete response.Methods: Clinical, laboratory, and therapeutic data from 44 Caucasian TRAPS patients treated with biologic agents were retrospectively collected in 16 Italian tertiary Centers.Results: A total of 55 biological courses with anakinra (n = 26), canakinumab (n = 16), anti-TNF-α agents (n = 10), and tocilizumab (n = 3) were analyzed. A complete response was observed in 41 (74.5%) cases, a partial response in 9 (16.4%) cases and a treatment failure in 5 (9.1%) cases. The frequency of TRAPS exacerbation…

0301 basic medicinemedicine.medical_specialtyMedicine (General)Settore MED/16 - REUMATOLOGIAmedicine.drug_classtumor necrosis factor inhibitorsbiologic therapy interleukin-1 inhibitors personalized medicine tocilizumab tumor necrosis factor inhibitors tumor necrosis factor receptor-associated periodic syndromeinterleukin-1 inhibitorsGastroenterology03 medical and health scienceschemistry.chemical_compoundtocilizumab0302 clinical medicineTocilizumabR5-920Internal medicinemedicinebiologic therapyAdverse effecttumor necrosis factor receptor-associated periodic syndromeOriginal Research030203 arthritis & rheumatologyAnakinraProteinuriabiologymedicine.diagnostic_testbusiness.industryC-reactive proteinGeneral MedicineTumor necrosis factor receptor associated periodic syndromepersonalized medicineCanakinumab030104 developmental biologychemistryErythrocyte sedimentation ratebiology.proteinAutoinflammationCorticosteroidMedicinemedicine.symptombusinessmedicine.drugbiologic therapy; interleukin-1 inhibitors; personalized medicine; tocilizumab; tumor necrosis factor inhibitors; tumor necrosis factor receptor-associated periodic syndrome
researchProduct

THU0569 MANAGEMENT OF ADULT-ONSET STILL’S DISEASE (AOSD) WITH IL-1 INHIBITORS: EVIDENCE- AND CONSENSUS-BASED STATEMENTS BY A PANEL OF ITALIAN EXPERTS

2019

Background: Still’s disease is a rare autoinflammatory disease, presenting in both pediatric [systemic juvenile idiopathic arthritis (SJIA)] and adult patients [adult-onset Still’s disease (AOSD]. Due to the rarity of the disease, clinical trials are limited and treatment guidelines are not available. In patients refractory to the classical therapy with NSAIDs, corticosteroids and DMARDs, the introduction of drugs targeting IL-1 has greatly expanded treatment options. Among these, canakinumab, a human monoclonal anti-IL-1β antibody, and anakinra, a human recombinant IL-1RA, have been recently approved for the treatment of refractory patients. Objectives: To produce recommendations, based on…

030203 arthritis & rheumatology0301 basic medicinemedicine.medical_specialtyAnakinraAdult-onset Still's diseaseAdult patientsbusiness.industryTreatment optionsBiologic treatmentClinical trial03 medical and health sciencesCanakinumab030104 developmental biology0302 clinical medicineFamily medicinemedicineIn patientbusinessmedicine.drugPoster Presentations
researchProduct

Lähentymistä kylmän sodan sallimissa rajoissa : Unkarin ulkopoliittiset suhteet Suomeen 1960-luvulla rauhanomaisen rinnakkaiselon, puolueettomuuden j…

2008

1960-lukupuolueettomuussukulaisuusrauhanomainen rinnakkaiseloSuomiulkopolitiikkakansainväliset suhteetheimoaatekylmä sotahistoriaUnkarirauhankumppanuusrinnakkaiselo
researchProduct

Exotic Meats: An Alternative Food Source

2019

International audience; Exotic meats were a protein source for human diet for many years. However, the massive capture caused the overexploitation and placed many reptiles and amphibious on the verge of extinction. Therefore, the captive rearing, the control during slaughtering and processing has been proposed as an alternative to the capture of wild animals. The present chapter shows the nutritional composition of this kind of meat, characterized by low levels of fat, high contents of protein, essential amino acids, fatty acids (especially long-chain n-3) and minerals indicating that their consumption may be beneficial for human health. However, very little data is available on the nutriti…

2. Zero hunger0303 health sciencessnakebusiness.industryNutritional composition[SDV]Life Sciences [q-bio]0402 animal and dairy scienceA proteinIntroduced species04 agricultural and veterinary sciencesturtleBiology040201 dairy & animal sciencefrog[SHS]Humanities and Social Scienceslizards03 medical and health sciencesOverexploitationHuman healthAgriculture[INFO]Computer Science [cs]Food sciencebusinesscrocodile030304 developmental biology
researchProduct

Anakinra for severe forms of COVID-19

2020

2019-20 coronavirus outbreakAnakinraRheumatologyCoronavirus disease 2019 (COVID-19)business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyImmunology and AllergyMedicinebusinessVirologyArticlemedicine.drugThe Lancet Rheumatology
researchProduct

Inattention and Uncertainty in the Predictive Brain

2021

Negative effects of inattention on task performance can be seen in many contexts of society and human behavior, such as traffic, work, and sports. In traffic, inattention is one of the most frequently cited causal factors in accidents. In order to identify inattention and mitigate its negative effects, there is a need for quantifying attentional demands of dynamic tasks, with a credible basis in cognitive modeling and neuroscience. Recent developments in cognitive science have led to theories of cognition suggesting that brains are an advanced prediction engine. The function of this prediction engine is to support perception and action by continuously matching incoming sensory input with to…

6162 Cognitive sciencecomputational modelingMatching (statistics)Computer sciencemedia_common.quotation_subjectpredictive processingappropriate uncertaintyocclusionTask (project management)03 medical and health sciences0302 clinical medicineNeuroimagingPerceptiondrivingRC346-429Function (engineering)tarkkaavaisuusennakointi030304 developmental biologymedia_common0303 health sciencesCognitionkognitiiviset prosessitepävarmuusautoilijatAction (philosophy)NormativeNeurology. Diseases of the nervous system030217 neurology & neurosurgeryCognitive psychology
researchProduct

Zinātnieku nakts

2010

2010. gada 24. septembra Zinātnieku nakts pasākumu piedāvājums LU Botāniskajā dārzā.

:NATURAL SCIENCES::Biology [Research Subject Categories]Zinātnieku naktsLU Botāniskais dārzs
researchProduct